Boston Scientific (NYSE:BSX) shares have seen a significant bump today after the company released preliminary fourth quarter and fiscal year 2017 earnings that topped The Street and showed growth of approximately 9.9% and 7.9%, respectively.
For the fourth quarter, the Marlborough, Mass.-based company said it expects to report sales of $2.4 billion, just in line with the approximate $2.4 billion consensus on Wall Street.
The quarterly results represent 9.9% growth on a reported basis, 8.1% on an operational basis and approximately 6.8% on an organic basis, the company said in a press release.
For the full year, Boston Scientific said it expects to report sales of $9.1 billion, which is just ahead of the $9 billion consensus on The Street and representing growth of 7.9% on a reported basis. 7.8% on an operational basis and 6.6% on an organic basis.
Shares in Boston Scientific have risen 8.2% so far today, at $27.92 as of 3:16 p.m. EST.
Last month, Boston Scientific said it won FDA approval for its Vercise deep brain stimulation system designed to treat symptoms of Parkinson’s disease.